Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
Infinimmune closed a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance two wholly owned, half-life-extended antibodies for atopic dermatitis. IFX-101 targets IL-22 and IFX-201 targets IL-13; both are expected…
